- Home
- SOL vs ACOG Comparison
SOL vs ACOG Comparison
Compare SOL & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- ACOG
- Stock Information
- Founded
- SOL 2005
- ACOG 2000
- Country
- SOL United States
- ACOG Canada
- Employees
- SOL N/A
- ACOG N/A
- Industry
- SOL Semiconductors
- ACOG
- Sector
- SOL Technology
- ACOG
- Exchange
- SOL Nasdaq
- ACOG Nasdaq
- Market Cap
- SOL 84.6M
- ACOG 80.3M
- IPO Year
- SOL 2008
- ACOG N/A
- Fundamental
- Price
- SOL $1.50
- ACOG $7.40
- Analyst Decision
- SOL Buy
- ACOG Strong Buy
- Analyst Count
- SOL 3
- ACOG 1
- Target Price
- SOL $3.50
- ACOG $20.00
- AVG Volume (30 Days)
- SOL 160.9K
- ACOG 80.0K
- Earning Date
- SOL 05-22-2025
- ACOG 05-15-2025
- Dividend Yield
- SOL N/A
- ACOG N/A
- EPS Growth
- SOL N/A
- ACOG N/A
- EPS
- SOL N/A
- ACOG N/A
- Revenue
- SOL $92,067,000.00
- ACOG N/A
- Revenue This Year
- SOL N/A
- ACOG N/A
- Revenue Next Year
- SOL $45.37
- ACOG N/A
- P/E Ratio
- SOL N/A
- ACOG N/A
- Revenue Growth
- SOL N/A
- ACOG N/A
- 52 Week Low
- SOL $1.04
- ACOG $3.75
- 52 Week High
- SOL $3.00
- ACOG $7.00
- Technical
- Relative Strength Index (RSI)
- SOL 57.84
- ACOG N/A
- Support Level
- SOL $1.25
- ACOG N/A
- Resistance Level
- SOL $1.40
- ACOG N/A
- Average True Range (ATR)
- SOL 0.07
- ACOG 0.00
- MACD
- SOL 0.03
- ACOG 0.00
- Stochastic Oscillator
- SOL 91.94
- ACOG 0.00
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.